(detection,2.8701690505786455)
(mammography,2.8701690505786455)
(HER2,2.8701690505786455)
(associated,2.8701690505786455)
(However,2.8701690505786455)
(imaging,2.505525936990736)
(rapidly,2.3513752571634776)
(fee-for-service,2.3513752571634776)
(presenting,2.3513752571634776)
(techniques,2.3513752571634776)
(1200,2.3513752571634776)
(formulation,2.3513752571634776)
(Observational,2.3513752571634776)
(body,2.3513752571634776)
(ondata,2.3513752571634776)
(conventional,2.3513752571634776)
(Selective,2.3513752571634776)
(special,2.3513752571634776)
(protected,2.3513752571634776)
(harmless,2.3513752571634776)
(general,2.3513752571634776)
(tend,2.3513752571634776)
(physical,2.3513752571634776)
(side,2.3513752571634776)
(53.7,2.3513752571634776)
(present,2.3513752571634776)
(35,2.3513752571634776)
(adjustment,2.3513752571634776)
(medicine,2.3513752571634776)
(0.50-0.99;,2.3513752571634776)
(assessment,2.3513752571634776)
(evidenced,2.3513752571634776)
(highest,2.3513752571634776)
(scrutiny,2.3513752571634776)
(PI3K/Akt/mTOR,2.3513752571634776)
(requiring,2.3513752571634776)
(Similar,2.3513752571634776)
(initial,2.3513752571634776)
(include,2.3513752571634776)
(flow,2.3513752571634776)
(.013,2.3513752571634776)
(2012,2.3513752571634776)
(palliative,2.3513752571634776)
(concept,2.3513752571634776)
(Extra-Terminal,2.3513752571634776)
(6.1%,2.3513752571634776)
(intervention,2.3513752571634776)
(CIs,2.3513752571634776)
(adoption,2.3513752571634776)
(44%,2.3513752571634776)
(MEK,2.3513752571634776)
(suggesting,2.3513752571634776)
(recovery,2.3513752571634776)
(counseling,2.3513752571634776)
(Group,2.3513752571634776)
(generated,2.3513752571634776)
(rising,2.3513752571634776)
(prescriptions,2.3513752571634776)
(Ulm,2.3513752571634776)
(immunohistochemistry,2.3513752571634776)
(<,2.3513752571634776)
(asymptomatic,2.3513752571634776)
(improve,2.3513752571634776)
(monitoring,2.3513752571634776)
(will,2.3513752571634776)
(carcinogenesis,2.3513752571634776)
(analyzing,2.3513752571634776)
(combination,2.3513752571634776)
(agreement,2.3513752571634776)
(3,2.3513752571634776)
(system-both,2.3513752571634776)
(hinder,2.3513752571634776)
(intrauterine,2.3513752571634776)
(test,2.3513752571634776)
(LEVEL,2.3513752571634776)
(paradigm,2.3513752571634776)
(molecule,2.3513752571634776)
(inhibitory,2.3513752571634776)
(high-dose,2.3513752571634776)
(Bromodomain,2.3513752571634776)
(Because,2.3513752571634776)
(resonance,2.3513752571634776)
(01.01.2010,2.3513752571634776)
(editing,2.3513752571634776)
(Tumour,2.3513752571634776)
(death,2.3513752571634776)
(acute,2.3513752571634776)
(investigations,2.3513752571634776)
(criteria,2.3513752571634776)
(barriers,2.3513752571634776)
(latest,2.3513752571634776)
(Notably,2.3513752571634776)
(date,2.3513752571634776)
(Aims,2.3513752571634776)
(p,2.3513752571634776)
(allowed,2.3513752571634776)
(mice,2.3513752571634776)
(IMAGING,2.3513752571634776)
(intravenous,2.3513752571634776)
(properly,2.3513752571634776)
(People,2.3513752571634776)
(drains,2.3513752571634776)
(increment,2.3513752571634776)
(monoclonal,2.3513752571634776)
(Colorectal,2.3513752571634776)
(pursue,2.3513752571634776)
(36,2.3513752571634776)
(recombination,2.3513752571634776)
(method,2.3513752571634776)
(confirmation,2.3513752571634776)
(required,2.3513752571634776)
(predictive,2.3513752571634776)
(Fatigue.In,2.3513752571634776)
(56%,2.3513752571634776)
(subcutaneous,2.3513752571634776)
(10.0%,2.3513752571634776)
(greater,2.3513752571634776)
(met,2.3513752571634776)
(Nine,2.3513752571634776)
(ER+,2.3513752571634776)
(remained,2.3513752571634776)
(imagesneed,2.3513752571634776)
(Both,2.3513752571634776)
(proportional,2.3513752571634776)
(Meta-regression,2.3513752571634776)
(moist,2.3513752571634776)
(Raf,2.3513752571634776)
(rapid,2.3513752571634776)
(46.0,2.3513752571634776)
(preclinical,2.3513752571634776)
(fluorescence,2.3513752571634776)
(MAGN,2.3513752571634776)
(protocol,2.3513752571634776)
(spite,2.3513752571634776)
(calculate,2.3513752571634776)
(ERK,2.3513752571634776)
(Unfortunately,2.3513752571634776)
(substantial,2.3513752571634776)
(tumour-related,2.3513752571634776)
(simplify,2.3513752571634776)
(Better,2.3513752571634776)
(continuing,2.3513752571634776)
(considering,2.3513752571634776)
(induction,2.3513752571634776)
(motivation,2.3513752571634776)
(relative,2.3513752571634776)
(preliminary,2.3513752571634776)
(symptom,2.3513752571634776)
(classify,2.3513752571634776)
(52,723,2.3513752571634776)
(14,2.3513752571634776)
(refractory,2.3513752571634776)
(stratified,2.3513752571634776)
(60%,2.3513752571634776)
(underwent,2.3513752571634776)
(evaluated,2.3513752571634776)
(Technical,2.3513752571634776)
(alternative,2.3513752571634776)
(routinely,2.3513752571634776)
(excision,2.3513752571634776)
(ion,2.3513752571634776)
(similar,2.3513752571634776)
(values,2.3513752571634776)
(AND,2.3513752571634776)
(15.3%,2.3513752571634776)
(8/18,2.3513752571634776)
(personalistic,2.3513752571634776)
(purposively,2.3513752571634776)
(States,2.3513752571634776)
(500,000,2.3513752571634776)
(checkpoint,2.3513752571634776)
(comprehensive,2.3513752571634776)
(system,number,2.3513752571634776)
(optoacoustic,2.3513752571634776)
(formation,2.3513752571634776)
(Information,2.3513752571634776)
(generally,2.3513752571634776)
(inquiry,2.3513752571634776)
(clustering,2.3513752571634776)
(variable,2.3513752571634776)
(intra-operative,2.3513752571634776)
(trastuzumab-induced,2.3513752571634776)
(0.70,2.3513752571634776)
(0.049,2.3513752571634776)
(12.4%,2.3513752571634776)
(regional,2.3513752571634776)
(frequently,2.3513752571634776)
(developments,2.3513752571634776)
(PR,2.3513752571634776)
(dynamic,2.3513752571634776)
(Negative,2.3513752571634776)
(choice,2.3513752571634776)
(avoid,2.3513752571634776)
(b-cryptoxanthin,2.3513752571634776)
(PubMed,2.3513752571634776)
(semi-quantitatively,2.3513752571634776)
(chromatin,2.3513752571634776)
(consultation,2.3513752571634776)
(DWI,2.3513752571634776)
(yielded,2.3513752571634776)
(utilized,2.3513752571634776)
(P,2.3513752571634776)
(apoptosis,2.3513752571634776)
(corresponding,2.3513752571634776)
(CDDP,2.3513752571634776)
(exploit,2.3513752571634776)
(prediagnosis,2.3513752571634776)
(microRNA,2.3513752571634776)
(experiment,2.3513752571634776)
(Result,2.3513752571634776)
(applications,2.3513752571634776)
(towavelet,2.3513752571634776)
(93.45%,2.3513752571634776)
(advance,2.3513752571634776)
(trial,2.3513752571634776)
(replaced,2.3513752571634776)
(January,2.3513752571634776)
(clearly,2.3513752571634776)
(28,2.3513752571634776)
(37.5%,2.3513752571634776)
(policy,2.3513752571634776)
(sampling,2.3513752571634776)
(inhibitor-,2.3513752571634776)
(collected,2.3513752571634776)
(BMI,2.3513752571634776)
(DiR,2.3513752571634776)
(Forty-two,2.3513752571634776)
(directly,2.3513752571634776)
(0.015,2.3513752571634776)
(ILC,2.3513752571634776)
(length,2.3513752571634776)
(Guided,2.3513752571634776)
(focusing,2.3513752571634776)
(Transcripts,2.3513752571634776)
(retinol,2.3513752571634776)
(causation,2.3513752571634776)
(search,2.3513752571634776)
(P=0.2,2.3513752571634776)
(shared,2.3513752571634776)
(multiresolution,2.3513752571634776)
(spectrometry,2.3513752571634776)
(23,2.3513752571634776)
(bed,2.3513752571634776)
(compare,2.3513752571634776)
(discomfort,2.3513752571634776)
(addition,2.3513752571634776)
(Finally,2.3513752571634776)
(face-to-face,2.3513752571634776)
(summarize,2.3513752571634776)
(potent,2.3513752571634776)
(compounds,2.3513752571634776)
(3.5,2.3513752571634776)
(misdiagnosis,2.3513752571634776)
(definitive,2.3513752571634776)
(OF,2.3513752571634776)
(validated,2.3513752571634776)
(50,2.3513752571634776)
(proportion,2.3513752571634776)
(adjuvant,2.3513752571634776)
(Osteopontin-750,2.3513752571634776)
(unenhanced,2.3513752571634776)
(Objective,2.3513752571634776)
(ratio,2.3513752571634776)
(atechnique,2.3513752571634776)
(shift,2.3513752571634776)
(assessed,2.3513752571634776)
(intensity,2.3513752571634776)
(1062,2.3513752571634776)
(behaviors,2.3513752571634776)
(Methods,2.3513752571634776)
(negligible,2.3513752571634776)
(diagnoses,2.3513752571634776)
(study;,2.3513752571634776)
(Six,2.3513752571634776)
(overview,2.3513752571634776)
(larger,2.3513752571634776)
(theory,2.3513752571634776)
(numbers,2.3513752571634776)
(explained,2.3513752571634776)
(Diagnostic,2.3513752571634776)
(An,2.3513752571634776)
(examinations,2.3513752571634776)
(update,2.3513752571634776)
(lower,2.3513752571634776)
(investigate,2.3513752571634776)
(broader,2.3513752571634776)
(Interestingly,2.3513752571634776)
(At,2.3513752571634776)
(MCL-1,2.3513752571634776)
(lutein,2.3513752571634776)
(filters,2.3513752571634776)
(offer,2.3513752571634776)
(biocompatibility,2.3513752571634776)
(RESON,2.3513752571634776)
(ER,2.3513752571634776)
(estradiol,2.3513752571634776)
(Multivariate,2.3513752571634776)
(interview,2.3513752571634776)
(signaling,2.3513752571634776)
(6.8%,2.3513752571634776)
(Ten,2.3513752571634776)
(Noteworthy,2.3513752571634776)
(p53,2.3513752571634776)
(breast-conserving,2.3513752571634776)
(cost,2.3513752571634776)
(precision,2.3513752571634776)
(Given,2.3513752571634776)
(radiologists,2.3513752571634776)
(prior,2.3513752571634776)
(detectionof,2.3513752571634776)
(investigation,2.3513752571634776)
(reproducibility,2.3513752571634776)
(phantom,2.3513752571634776)
(helps,2.3513752571634776)
(self-examination,2.3513752571634776)
(summarized,2.3513752571634776)
(paper,2.3513752571634776)
(All,2.3513752571634776)
(BAK,2.3513752571634776)
(hormone,2.3513752571634776)
(38.7%,2.3513752571634776)
(shaped,2.3513752571634776)
(1,444,2.3513752571634776)
(segmentation,2.3513752571634776)
(estimated,2.3513752571634776)
(oxide,2.3513752571634776)
(IO-NP,2.3513752571634776)
(versus,2.3513752571634776)
(trastuzumab,2.3513752571634776)
(Comparison,2.3513752571634776)
(0.75-1.09,2.3513752571634776)
(HER4,2.3513752571634776)
(crucial,2.3513752571634776)
(difficult,2.3513752571634776)
(17,2.3513752571634776)
(lethality,2.3513752571634776)
(breasts,2.3513752571634776)
(cancercells,2.3513752571634776)
(onset,2.3513752571634776)
(subtype,2.3513752571634776)
(acquisition,2.3513752571634776)
(finances,2.3513752571634776)
(ml,2.3513752571634776)
(network,2.3513752571634776)
(capecitabine,2.3513752571634776)
(multispectral,2.3513752571634776)
(HER3,2.3513752571634776)
(vs,2.3513752571634776)
(leading,2.3513752571634776)
(Efficacy,2.3513752571634776)
(pattern,2.3513752571634776)
(54%,2.3513752571634776)
(modified,2.3513752571634776)
(pathological,2.3513752571634776)
(applicable,2.3513752571634776)
(5,2.3513752571634776)
(1996,2.3513752571634776)
(31.12.2014,2.3513752571634776)
(Centre,2.3513752571634776)
(aggressive,2.3513752571634776)
(So,2.3513752571634776)
(inception,2.3513752571634776)
(Cardiac,2.3513752571634776)
(noncoding,2.3513752571634776)
(computed,2.3513752571634776)
(43.6,2.3513752571634776)
(coronary,2.3513752571634776)
(mortality,2.3513752571634776)
(Anthracyclines,2.3513752571634776)
(Ulceration,2.3513752571634776)
(BAX,2.3513752571634776)
(inclusion,2.3513752571634776)
(pill,2.3513752571634776)
(wider,2.3513752571634776)
(administration,2.3513752571634776)
(treatment;,2.3513752571634776)
(Among,2.3513752571634776)
(normal,2.3513752571634776)
(T/B,2.3513752571634776)
(adjusted,2.3513752571634776)
(scan,2.3513752571634776)
(typical,2.3513752571634776)
(Ag2S-NP,2.3513752571634776)
(cardiotoxicities,2.3513752571634776)
(VEGFB,2.3513752571634776)
(recently,2.3513752571634776)
(occurred,2.3513752571634776)
(copyright,2.3513752571634776)
(2.5Â h,2.3513752571634776)
(Ras,2.3513752571634776)
(AZD2281,2.3513752571634776)
(peptide,2.3513752571634776)
(distinguish,2.3513752571634776)
(interpretation,2.3513752571634776)
(well,2.3513752571634776)
(discovered,2.3513752571634776)
(lag,2.3513752571634776)
(defined,2.3513752571634776)
(Anti-HER2,2.3513752571634776)
(occurrence,2.3513752571634776)
(cytotoxicity,2.3513752571634776)
(maintaining,2.3513752571634776)
(3.0,2.3513752571634776)
(PET/CT,2.3513752571634776)
(32.1,2.3513752571634776)
(intrinsic,2.3513752571634776)
(historically,2.3513752571634776)
(rates,2.3513752571634776)
(number,2.3513752571634776)
(Performing,2.3513752571634776)
(chemokine,2.3513752571634776)
(secondary,2.3513752571634776)
(detected,2.3513752571634776)
(gadolinium-based,2.3513752571634776)
(g/day,2.3513752571634776)
(Conservative,2.3513752571634776)
(RAD51,2.3513752571634776)
(dense,2.3513752571634776)
(young,2.3513752571634776)
(representative,2.3513752571634776)
(III,2.3513752571634776)
(disproportionate,2.3513752571634776)
(reviewed,2.3513752571634776)
(acromegaly,2.3513752571634776)
(views,2.3513752571634776)
(9.7,2.3513752571634776)
(course,2.3513752571634776)
(finding,2.3513752571634776)
(Conventional,2.3513752571634776)
(early-onset,2.3513752571634776)
(mutational,2.3513752571634776)
(7.0%,2.3513752571634776)
(medical,2.3513752571634776)
(2016,2.3513752571634776)
(Filipino,2.3513752571634776)
(7/18,2.3513752571634776)
(shorten,2.3513752571634776)
(designed,2.3513752571634776)
(apparent,2.3513752571634776)
(radiology,2.3513752571634776)
(581,2.3513752571634776)
(subjective,2.3513752571634776)
(16.4,2.3513752571634776)
(wound,2.3513752571634776)
(urgently,2.3513752571634776)
(axillary,2.3513752571634776)
(cross-sectional,2.3513752571634776)
(lines,2.3513752571634776)
(differential,2.3513752571634776)
(lowest,2.3513752571634776)
(non-ideal,2.3513752571634776)
(mammographic,2.3513752571634776)
(potential,2.3513752571634776)
(breast/axillary,2.3513752571634776)
(locally,2.3513752571634776)
(massive,2.3513752571634776)
(treatments,2.3513752571634776)
(newly,2.3513752571634776)
(ethinyl,2.3513752571634776)
(plan,2.3513752571634776)
(31,2.3513752571634776)
(Ras/MAPK,2.3513752571634776)
(P=0.4,2.3513752571634776)
(Twenty-six,2.3513752571634776)
(missed,2.3513752571634776)
(mean,2.3513752571634776)
(epigenetic,2.3513752571634776)
(Triple,2.3513752571634776)
(performance,2.3513752571634776)
(filter,2.3513752571634776)
(radical,2.3513752571634776)
(coupled,2.3513752571634776)
(undetectable,2.3513752571634776)
(co-encapsulation,2.3513752571634776)
(wane,2.3513752571634776)
(dermatitis,2.3513752571634776)
(collect,2.3513752571634776)
(fluorophore,2.3513752571634776)
(transferable,2.3513752571634776)
(cardiotoxicity;,2.3513752571634776)
(perception,2.3513752571634776)
(derived,2.3513752571634776)
(0-3012.5,2.3513752571634776)
(feasible;,2.3513752571634776)
(random,2.3513752571634776)
(GSK525762A,2.3513752571634776)
(They,2.3513752571634776)
(0.02;,2.3513752571634776)
(anthracycline,2.3513752571634776)
(precise,2.3513752571634776)
(term,2.3513752571634776)
(Thus,2.3513752571634776)
(burden,2.3513752571634776)
(constructing,2.3513752571634776)
(consistent,2.3513752571634776)
(appears,2.3513752571634776)
(neural,2.3513752571634776)
(Metastases,2.3513752571634776)
(without,2.3513752571634776)
(According,2.3513752571634776)
(preferentially,2.3513752571634776)
(interference,2.3513752571634776)
(release,2.3513752571634776)
(Studies,2.3513752571634776)
(19,2.3513752571634776)
(times,2.3513752571634776)
(detectability,2.3513752571634776)
(specificities,2.3513752571634776)
(appropriateness,2.3513752571634776)
(inhibitors-based,2.3513752571634776)
(concurrently,2.3513752571634776)
(susceptibility,2.3513752571634776)
(fear,2.3513752571634776)
(difficulty,2.3513752571634776)
(familial,2.3513752571634776)
(CRISPR-Cas9-based,2.3513752571634776)
(minimal,2.3513752571634776)
(importantly,2.3513752571634776)
(safety,2.3513752571634776)
(Fluorescence,2.3513752571634776)
(Healthcare,2.3513752571634776)
(non-functioning,2.3513752571634776)
(0.93,2.3513752571634776)
(tumors,2.3513752571634776)
(cardiovascular,2.3513752571634776)
(commonly,2.3513752571634776)
(underutilized,2.3513752571634776)
(drugs,2.3513752571634776)
("all-in-one",2.3513752571634776)
(iron,2.3513752571634776)
(Improved,2.3513752571634776)
(72,2.3513752571634776)
(transforms,2.3513752571634776)
(makers,2.3513752571634776)
(older,2.3513752571634776)
(Patient,2.3513752571634776)
(routine,2.3513752571634776)
(cytometry,2.3513752571634776)
(conserving,2.3513752571634776)
(classifier,2.3513752571634776)
(play,2.3513752571634776)
(Using,2.3513752571634776)
(untargeted,2.3513752571634776)
(a.u,2.3513752571634776)
(20-mcg,2.3513752571634776)
(expenditures,2.3513752571634776)
(combinations,2.3513752571634776)
(formed,2.3513752571634776)
(a-carotene,2.3513752571634776)
(visual,2.3513752571634776)
(aforementioned,2.3513752571634776)
(vulnerability,2.3513752571634776)
(nude,2.3513752571634776)
(Database,2.3513752571634776)
(impaired,2.3513752571634776)
(inheritance,2.3513752571634776)
(Forty-three,2.3513752571634776)
(sisters',2.3513752571634776)
(younger,2.3513752571634776)
(eg,2.3513752571634776)
(diffusion-weighted,2.3513752571634776)
(address,2.3513752571634776)
(exam,2.3513752571634776)
(tumor-specific,2.3513752571634776)
(12.1%,2.3513752571634776)
(PGF,2.3513752571634776)
(advances,2.3513752571634776)
(entity,2.3513752571634776)
(timing,2.3513752571634776)
(marked,2.3513752571634776)
(incorporate,2.3513752571634776)
(Similarly,2.3513752571634776)
(tracer,2.3513752571634776)
(consultations,2.3513752571634776)
(Conclusions,2.3513752571634776)
(Radiotherapy,2.3513752571634776)
(immunotherapy-based,2.3513752571634776)
(2005-2017,2.3513752571634776)
(longer,2.3513752571634776)
(9.5,2.3513752571634776)
(levonorgestrel,2.3513752571634776)
(modalities,2.3513752571634776)
(properties,2.3513752571634776)
(After,2.3513752571634776)
(United,2.3513752571634776)
(unusual,2.3513752571634776)
(bleeding,2.3513752571634776)
(transtuzumab-induced,2.3513752571634776)
(widespread,2.3513752571634776)
(supplement,2.3513752571634776)
(lycopene,2.3513752571634776)
(prolonged,2.3513752571634776)
(predict,2.3513752571634776)
(filled,2.3513752571634776)
(BCL-2,2.3513752571634776)
(mannose,2.3513752571634776)
(elderly,2.3513752571634776)
(responsible,2.3513752571634776)
(Seroma,2.3513752571634776)
(HER1,2.3513752571634776)
(Mammography,2.3513752571634776)
(0.88-0.99;,2.3513752571634776)
(demographics,2.3513752571634776)
(promising,2.3513752571634776)
(established,2.3513752571634776)
(underlines,2.3513752571634776)
(order,2.3513752571634776)
(suspicion,2.3513752571634776)
(detecting,2.3513752571634776)
(Future,2.3513752571634776)
(accomplished,2.3513752571634776)
(consistently,2.3513752571634776)
(proliferation,2.3513752571634776)
(node,2.3513752571634776)
(20%,2.3513752571634776)
(clear,2.3513752571634776)
(experience,2.3513752571634776)
(classification,2.3513752571634776)
(injection,2.3513752571634776)
(Despite,2.3513752571634776)
(0.033;,2.3513752571634776)
(ultrasound,2.3513752571634776)
(living,2.3513752571634776)
(post-injection,2.3513752571634776)
(thesuspicious,2.3513752571634776)
(region,2.3513752571634776)
(called,2.3513752571634776)
(led,2.3513752571634776)
(Female,2.3513752571634776)
(lack,2.3513752571634776)
(earlier,2.3513752571634776)
(rights,2.3513752571634776)
(regulating,2.3513752571634776)
(comparing,2.3513752571634776)
(NPV,2.3513752571634776)
(EVIDENCE,2.3513752571634776)
(tools,2.3513752571634776)
(malign,2.3513752571634776)
(utilizing,2.3513752571634776)
(Efforts,2.3513752571634776)
(For,2.3513752571634776)
(uptake,2.3513752571634776)
(axilla,2.3513752571634776)
(results,2.3513752571634776)
(19,450,2.3513752571634776)
(semi-structured,2.3513752571634776)
(Cooperative,2.3513752571634776)
(symptoms,2.3513752571634776)
(University,2.3513752571634776)
(possibility,2.3513752571634776)
(Her,2.3513752571634776)
(dysfunction,2.3513752571634776)
(details,2.3513752571634776)
(VEGFC,2.3513752571634776)
(described,2.3513752571634776)
(postmenopausal,2.3513752571634776)
(at-risk,2.3513752571634776)
(thematic,2.3513752571634776)
(2004,2.3513752571634776)
(completing,2.3513752571634776)
(delay,2.3513752571634776)
(necessity,2.3513752571634776)
(desquamation,2.3513752571634776)
(deterioration,2.3513752571634776)
(exhibiting,2.3513752571634776)
(locus,2.3513752571634776)
(utility,2.3513752571634776)
(557,2.3513752571634776)
(nanoparticle,2.3513752571634776)
(unresectable,2.3513752571634776)
(beam,2.3513752571634776)
(populations,2.3513752571634776)
(inhibitor/mimic-,2.3513752571634776)
(dye,2.3513752571634776)
(defines,2.3513752571634776)
(chart,2.3513752571634776)
(osteopontin-750,2.3513752571634776)
(functional,2.3513752571634776)
(member,2.3513752571634776)
(Hospital,2.3513752571634776)
(confirms,2.3513752571634776)
(Altogether,2.3513752571634776)
(systematically,2.3513752571634776)
(validating,2.3513752571634776)
(decreases,2.3513752571634776)
(lapatinib,2.3513752571634776)
(excluded,2.3513752571634776)
(4,2.3513752571634776)
(trend,2.3513752571634776)
(triple-negative,2.3513752571634776)
(dose-dependent,2.3513752571634776)
(If,2.3513752571634776)
(respectively,2.3513752571634776)
(indicate,2.3513752571634776)
(pathways,2.3513752571634776)
(limited,2.3513752571634776)
(processing,2.3513752571634776)
(high-resolution,2.3513752571634776)
(reflect,2.3513752571634776)
(tissue,2.3513752571634776)
(8,2.3513752571634776)
(practice,2.3513752571634776)
(directionality,2.3513752571634776)
(appealing,2.3513752571634776)
(indicative,2.3513752571634776)
(numerous,2.3513752571634776)
(percent,2.3513752571634776)
(She,2.3513752571634776)
(targeting,2.3513752571634776)
(synthetic,2.3513752571634776)
(4.0%,2.3513752571634776)
(As,2.3513752571634776)
(Lung,2.3513752571634776)
(time-varying,2.3513752571634776)
(external,2.3513752571634776)
(contribute,2.3513752571634776)
(PEGylated,2.3513752571634776)
(harmfulor,2.3513752571634776)
(EMBASE,2.3513752571634776)
(10.3%,2.3513752571634776)
(sibling,2.3513752571634776)
(quality,2.3513752571634776)
(allotting,2.3513752571634776)
(invariance,2.3513752571634776)
(necessary,2.3513752571634776)
(perceive,2.3513752571634776)
(JQ1,2.3513752571634776)
(removed,2.3513752571634776)
(Early,2.3513752571634776)
(Cox,2.3513752571634776)
(40,000,2.3513752571634776)
(kg/m2,2.3513752571634776)
(mechanisms,2.3513752571634776)
(registries,2.3513752571634776)
(dose,2.3513752571634776)
(caner,2.3513752571634776)
(Locoregional,2.3513752571634776)
(one-year,2.3513752571634776)
(cornerstone,2.3513752571634776)
(regulate,2.3513752571634776)
(powerful,2.3513752571634776)
(12-15%,2.3513752571634776)
(regression,2.3513752571634776)
(4.8,2.3513752571634776)
(phenomenological,2.3513752571634776)
(high-risk,2.3513752571634776)
(tissues,2.3513752571634776)
(0.001,2.3513752571634776)
(82.5,2.3513752571634776)
(cancer-specific,2.3513752571634776)
(NST,2.3513752571634776)
(generating,2.3513752571634776)
(computational,2.3513752571634776)
(25.8%,2.3513752571634776)
(multi-omics,2.3513752571634776)
(Thirteen,2.3513752571634776)
(transtuzumab,2.3513752571634776)
(limitations,2.3513752571634776)
(patient's,2.3513752571634776)
(To,2.3513752571634776)
(index,2.3513752571634776)
(selective,2.3513752571634776)
(pooled,2.3513752571634776)
(framework,2.3513752571634776)
(indicator,2.3513752571634776)
(Many,2.3513752571634776)
(cycle,2.3513752571634776)
(energy,2.3513752571634776)
(facilitate,2.3513752571634776)
(respondents,2.3513752571634776)
(extracted,2.3513752571634776)
(Due,2.3513752571634776)
(outperforms,2.3513752571634776)
(sulfide,2.3513752571634776)
(cell-related,2.3513752571634776)
(clinicians,2.3513752571634776)
(BCL-W,2.3513752571634776)
(digital,2.3513752571634776)
(beliefs,2.3513752571634776)
(curbing,2.3513752571634776)
(generate,2.3513752571634776)
(efficient,2.3513752571634776)
(175,2.3513752571634776)
(explore,2.3513752571634776)
(troponins,2.3513752571634776)
(cohort;,2.3513752571634776)
(MATERIALS,2.3513752571634776)
(experienced,2.3513752571634776)
(lobular,2.3513752571634776)
(addressed,2.3513752571634776)
(existing,2.3513752571634776)
(coefficients,2.3513752571634776)
(sampled,2.3513752571634776)
(antibodies,2.3513752571634776)
(15.9,2.3513752571634776)
(J,2.3513752571634776)
(ErbB,2.3513752571634776)
(toxicity,2.3513752571634776)
(VEGFA,2.3513752571634776)
(strategy,2.3513752571634776)
